ImmuPharma (LON:IMM) Trading 28.6% Higher - Here's What Happened

Key Points

• ImmuPharma's share price experienced a significant increase of 28.6% on Tuesday, with the stock reaching a high of GBX 12 ($0.16) before closing at GBX 11.30 ($0.15).
• The trading volume surged to 17,007,168 shares, which is a 97% increase compared to the average session volume.
• Despite the positive trading activity, the company reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter, with analysts forecasting an EPS of -339.0000022 for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price shot up 28.6% during trading on Tuesday . The stock traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). 17,007,168 shares traded hands during trading, an increase of 97% from the average session volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Trading Up 16.8%

The firm has a fifty day moving average of GBX 5.49 and a 200 day moving average of GBX 3.64. The company has a market capitalization of £65.96 million, a P/E ratio of -1,483.15 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.